Navigation Links
Sirion Therapeutics Partners With Advanced Vision Research (TheraTears(R)) to Promote Products for Retinal and Meibomian Gland Health

TAMPA, Fla., Feb. 16 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, today announced that it has entered into an agreement with Advanced Vision Research, Inc. (AVR) of Woburn, MA, to co-promote, within the U.S., AVR's new MacuTrition(R) oral retinal nutritional supplement and its recently launched NutriDox Convenience Kit for meibomian gland therapy.

AVR is a privately held ophthalmic specialty company and manufacturer of the popular over-the-counter TheraTears(R) dry-eye product line. The Sirion sales force will promote MacuTrition and the NutriDox Convenience Kit and provide sampling for the TheraTears line.

"The partnership with Advanced Vision Research continues and expands our mission to offer diversified products that will make a real difference to ophthalmologists and their patients," said Barry Butler, President and CEO of Sirion. "MacuTrition, the NutriDox Convenience Kit and the TheraTears product line dovetail strongly with our own products in development for dry AMD, dry eye and other ocular conditions."

"Sirion and Advanced Vision Research share a joint focus on healthy eyes for patients through clinical research and innovation in ocular disease," commented Jeffrey P. Gilbard, M.D., AVR founder, CEO and Chief Scientific Officer. Dr. Gilbard is Clinical Assistant Professor of Ophthalmology at Harvard Medical School, and Director of the Dry Eye and Ocular Surface Disease Clinic at the New England Eye Center in Boston. "Sirion's resources and specialized sales force will be instrumental in helping AVR promote retinal and meibomian gland health and provide relief for dry-eye patients."

MacuTrition is the first major oral nutritional supplement that addresses oxidation, inflammation and neovascularization, three very important processes that threaten long-term eye and general health, and play a key role in those at risk for macular degeneration and diabetic retinopathy. MacuTrition, available over-the-counter, is a combination of synergistic anti-oxidants, anti-inflammatories and anti-angiogenics, including fish-oil omega-3s, vitamin D, green tea extract and tocotrienol (vitamin E).

Meibomitis is inflammation of the meibomian glands that is a precursor to meibomian gland dysfunction (MGD), which is a cause of evaporative dry eye and is associated with ocular rosacea. Meibomitis is an incapacitating condition characterized by excess bacteria in the eye lid margins with increased vascularization of the lids, and loss of normal meibomian gland anatomy and function. This leads to diminished quality and diminished quantity of meibomian lipids, tear-film lipid layer deficiency and increased tear-film evaporation. The NutriDox Convenience Kit, available by prescription, includes doxycycline 75 mg, TheraTears Nutrition-a flaxseed oil/fish oil/vitamin E omega-3 supplement, and the iHeat(TM) portable warm compress system to help address these symptoms.

About Sirion Therapeutics, Inc.

Sirion Therapeutics is a privately held biopharmaceutical company pursuing the discovery, development, and commercialization of products addressing unmet medical needs in the protection and preservation of eyesight. Sirion's diverse product portfolio includes products that address ocular diseases and conditions including uveitis, herpetic keratitis, dry eye, glaucoma and geographic atrophy associated with dry AMD. For more information, please visit

About Advanced Vision Research, Inc.

Advanced Vision Research, with offices in Woburn, Massachusetts, develops and markets innovative pharmaceuticals for dry eye, external eye diseases and retinal health under the TheraTears(R), NutriDox(R) and MacuTrition(R) brands. The TheraTears line of products include Preservative-Free TheraTears, TheraTears in a bottle, TheraTears Liquid Gel, TheraTears Contact Lens Comfort Drops, TheraTears Nutrition (omega-3 supplement for dry eyes), and TheraTears brand SteriLid Eyelid Cleanser. Additional information is available at the Company's website at

SOURCE Sirion Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sirion Therapeutics Supports Ophthalmic Education
2. Sirion Therapeutics Acquires Worldwide License to Develop New Treatment for Ocular Diseases
3. Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium
4. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
5. Sirion Therapeutics Announces FDA Approval of Durezol(TM) for Treatment of Postoperative Ocular Inflammation and Pain
6. Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
11. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... ... Manufacturing Practice (GMP) 10000 in the Santiago Marriott. The Global Stem Cells Group ... by a world-class team of qualified medical researchers and practitioners, experienced in administering ...
(Date:11/30/2015)... 2015  An interventional radiology technique shows promise for helping ... of a study being presented today at the annual meeting ... (RSNA). --> --> ... interventional radiologists as a way to stop bleeding in emergency ... means of treating obesity is new. Mubin Syed ...
(Date:11/30/2015)... includes an MPP licen ... niversity , s Solid Drug Nanoparticle (SDN) Technology ; ... up through cost cuts of priority ... based anywhere in the world will have the right to make, use and distribute ... where licensees based anywhere in the world will have the right to make, use ...
(Date:11/30/2015)... HOLLISTON, Mass. , Nov. 30, 2015 /PRNewswire/ ... HART ), a biotechnology company developing bioengineered ... has received written notification from The NASDAQ Stock ... minimum bid price requirements. The letter noted that ... of HART,s common stock having exceeded $1.00 per ...
Breaking Biology Technology:
(Date:11/20/2015)... 2015 NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... was recently interviewed on The RedChip Money Report ... weekend on Bloomberg Europe , Bloomberg Asia, Bloomberg ... NXTD ) ("NXT-ID" or the "Company"), a biometric ...
(Date:11/19/2015)... YORK , Nov. 19, 2015  Although some ... market is dominated by a few companies, according to ... companies own 51% of the market share of the ... The World Market for Molecular Diagnostic s ... "The market is still controlled by one company ...
(Date:11/18/2015)... New York , November 18, 2015 ... Market Research has published a new market report titled ... Growth, Trends, and Forecast, 2015 - 2021. According to the ... in 2014 and is anticipated to reach US$29.1 bn ... to 2021. North America ...
Breaking Biology News(10 mins):